Foundation Medicine is transforming cancer care by providing patients, physicians and researchers with a deep understanding of the genomic mutations that drive cancer.

D1
For Providers
Foundation Medicine’s proven portfolio of tests and services offers the quality and commitment you need to help guide treatment strategies for your advanced cancer patients.
FoundationOne®CDx FoundationOne®Liquid CDx FoundationOne®HEME
Cardbio
For Biopharma & Research Partners
We can support you from initial discovery to launch of a new therapy with our global portfolio of tests and services and our scientific and regulatory experts to fit your specific needs. As a leader in companion diagnostic (CDx) approvals, we are your ideal partner to help make your next breakthrough a standard of care.
Discovery & Translational ResearchClinical Development & CDx
P1
For Patients
Every cancer is unique. That’s why we are committed to providing specific genomic insights into your cancer to help your doctor guide a personalized care plan.
Information For Patients

Proven Leadership

Extensively validated and continuously updated. The validations of our comprehensive genomic profiling services are published in top-tier peer-reviewed journals, and the services are supported by a large and growing body of clinical evidence.1-6 Our continuously growing genomic database currently includes over 800,000 genomic profiles in over 150 common and rare tumour subtypes, helping us to ensure our reporting of clinically-relevant genomic alterations is always up-to-date.7

FOUNDATION MEDICINE REPORTS DELIVERED*
Over 1.3 Million
OF ALL CDX APPROVALS INDICATIONS FOR NGS ACROSS THE US AND JAPAN8,9
60%
PEER-REVIEWED PUBLICATIONS7
800+

Valuable Insights, Actionable Options

Our tests help to identify the genomic alterations driving a patient's cancer and match them with relevant targeted therapies, immunotherapies, and clinical trial options.2-4
We also provide decision support services.

Patient Story

Treating cancer means more than just dealing with the disease; it also means treating the whole person. Christine Bray, ovarian cancer survivor, shares her journey to remission after obtaining a Foundation Medicine comprehensive genomic profiling test.

Reportimg

Actionable Insights Upfront

We understand that treatment planning for your cancer patients can be complex. That’s why we have a “Professional Services” summary section to the first page for our FoundationOne CDx and FoundationOne Liquid CDx reports . This will bring information for all reported biomarker and genomic findings and our new “Report Highlights” section upfront, to help you focus on the critical findings for your patients quicker and easier.

ADDITIONAL NOTES

Important Safety Information